IGC Pharma (IGC) Other Non-Current Liabilities (2011 - 2025)
IGC Pharma (IGC) posted quarterly Other Non-Current Liabilities of $16000.0 for Q1 2025, down 20.0% year-over-year from $20000.0 in Q1 2024, and little changed quarter-over-quarter from $16000.0 in Q4 2024.
IGC Pharma (IGC) Other Non-Current Liabilities (2011 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Other Non-Current Liabilities for 14 consecutive years, with $16000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Other Non-Current Liabilities fell 20.0% year-over-year to $16000.0; the TTM figure through Mar 2025 stood at $16000.0 (down 20.0% YoY), while the FY2025 annual figure was $16000.0, down 20.0% from the prior year.
- Other Non-Current Liabilities steadied at $16000.0 in Q1 2025 per IGC's latest filing, from $16000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $21000.0 in Q1 2023 and bottomed at $15000.0 in Q1 2021.
- Historically, Other Non-Current Liabilities has averaged $17058.8 across 5 years, with a median of $16000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities soared 31.25% — and 2025, when it dropped 20.0%.
- IGC Pharma's Other Non-Current Liabilities stood at $15000.0 in 2021, then changed by 0.0% to $15000.0 in 2022, then rose by 13.33% to $17000.0 in 2023, then slipped by 5.88% to $16000.0 in 2024, then changed by 0.0% to $16000.0 in 2025.
- Business Quant data shows IGC's Other Non-Current Liabilities at $16000.0 in Q1 2025, $16000.0 in Q4 2024, and $20000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 17,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 21,000.00 |
| Dec 31, 2022 | 15,000.00 |
| Sep 30, 2022 | 15,000.00 |
| Jun 30, 2022 | 16,000.00 |
| Mar 31, 2022 | 16,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 15,000.00 |
| Jun 30, 2021 | 15,000.00 |
| Mar 31, 2021 | 15,000.00 |
| Dec 31, 2020 | 17,000.00 |
| Sep 30, 2020 | 16,000.00 |
| Jun 30, 2020 | 16,000.00 |